Insulin Resistance in Women With Prolactinoma

This study has been completed.

Sponsor:

Information provided by:

Universidade Federal do Rio de Janeiro

ClinicalTrials.gov Identifier:

NCT00481299

First received: May 30, 2007

Last updated: NA

Last verified: April 2007

History: No changes posted

Purpose

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.

The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.

Condition
Prolactinoma Insulin Resistance Hyperlipidemia


Study Type:	Observational
Study Design:	Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective
Official Title:	Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists

Resource links provided by NLM:

Drug Information available for: Insulin Insulin human

Genetic and Rare Diseases Information Center resources: Galactorrhoea-Hyperprolactinaemia Prolactinoma

U.S. FDA Resources

Further study details as provided by Universidade Federal do Rio de Janeiro:


Enrollment:	2004
Study Start Date:	October 2004
Study Completion Date:	September 2006

Detailed Description:

A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.

Eligibility


Ages Eligible for Study:	18 Years to 48 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Prolactinoma
Female gender
Premenopausal

Exclusion Criteria:

Obesity (BMI ≥ 30 kg/m²)
Diabetes mellitus
Hypertension
GH deficiency
Hypothyroidism
Primary hypogonadism
Adrenal insufficiency
Pituitary surgery

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481299

Locations


Brazil
Clementino Fraga Filho University Hospital
Rio de Janeiro, RJ, Brazil

Sponsors and Collaborators

Universidade Federal do Rio de Janeiro

Investigators


Principal Investigator:	Erika CO Naliato, MSc	Federal University of Rio de Janeiro - Brazil

More Information


ClinicalTrials.gov Identifier:	NCT00481299 History of Changes
Other Study ID Numbers:	178/04
Study First Received:	May 30, 2007
Last Updated:	May 30, 2007

Keywords provided by Universidade Federal do Rio de Janeiro:


Insulin glucose lipids prolactinoma hyperprolactinemia

Additional relevant MeSH terms:


Insulin Resistance Hyperlipidemias Hyperlipoproteinemias Prolactinoma Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Dyslipidemias Lipid Metabolism Disorders Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms	Pituitary Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 25, 2017

To Top